-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
(3R)-5,7-Dihydroxy-3-(4-hydroxybenzyl)-6-methyl-2,3-dihydro-4H-1-benzopyran-4-one
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/84638-48-2.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 84638-48-2 |
| Description | (3R)-5,7-Dihydroxy-3-(4-hydroxybenzyl)-6-methyl-2,3-dihydro-4H-1-benzopyran-4-one is found in Dracaena cochinchinensis. |
Product Information
| Synonyms | (3R)-5,7-Dihydroxy-6-methyl-3-(4'-hydroxybenzyl)chroman-4-one; (3R)-5,7-dihydroxy-3-[(4-hydroxyphenyl)methyl]-6-methyl-chroman-4-one |
| Molecular Weight | 300.31 |
| Molecular Formula | C17H16O5 |
| Canonical SMILES | CC1=C(C2=C(C=C1O)OCC(C2=O)CC3=CC=C(C=C3)O)O |
| InChI | InChI=1S/C17H16O5/c1-9-13(19)7-14-15(16(9)20)17(21)11(8-22-14)6-10-2-4-12(18)5-3-10/h2-5,7,11,18-20H,6,8H2,1H3/t11-/m1/s1 |
| InChIKey | BFVOQLBTLZMHPR-LLVKDONJSA-N |
| Purity | 95% |
| Solubility | Methanol |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 404 |
| Exact Mass | 300.09977361 |
| In Vitro | LPRP-Et-97543 (0.625-40 μg/ml; 3 days) causes cytotoxic effects at doses >10 μg/ml in HepG2.2.15 and HBV-transfected Huh7 cells. LPRP-Et-97543 (2.5-10 μg/ml; 3 days) has inhibitory effects on HBsAg and HBeAg secretions. And the HBeAg inhibition rate is higher than the HBsAg inhibition rate in HepG2.2.15 cells. LPRP-Et-97543 (2.5-10 μg/ml; 2 days after transfected with pHBV1.2 plasmid for 2 days) significantly reduces both precore/pregenomic and major S/preS RNA with the LPRP-Et-97543 inhibition potential higher on surface RNA than on the precore/pregenomic RNA. |
| Target | HBV |
| XLogP3-AA | 3.2 |
